arrow
C

Clara Hwang

henry ford cancer institute
H指数:35
被引数:5,937

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer

吸烟、肿瘤遗传学与转移性前列腺癌患者预后的关联

2026-09-050
PRE
3 Safety Profile of Casdatifan Monotherapy in Patients with Clear Cell Renal Cell Carcinoma: Pooled Analysis of the ARC-20 Study (NCT05536141)

3 卡德拉替芬单药治疗透明细胞肾细胞癌患者的安全性特征:ARC-20研究(NCT05536141)的合并分析

2026-09-020
OAAI
Comparison of whole genome sequencing with clinical targeted panel sequencing of metastatic prostate cancer: insights from real-world data

比较转移性前列腺癌的全基因组测序与临床靶向基因 panel 测序:来自真实世界数据的见解

2026-07-250
OA
Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617

PSMA阳性转移性去势抵抗性前列腺癌患者接受177Lu-PSMA-617治疗后的基因组改变及关联结局

2025-11-010
PRE
Combination casdatifan plus cabozantinib in previously treated patients with clear cell renal cell carcinoma: results from an expansion cohort of ARC-20 (NCT05536141)

联合卡达提法尼和卡博扎替尼用于既往治疗过的透明细胞肾细胞癌患者的方案:ARC-20(NCT05536141)扩展队列的研究结果

2025-10-010
OAAI
Associations of COVID-19 vaccination with risks for post-infectious cardiovascular complications: an international cohort study in cancer patients with SARS-CoV-2 infection

COVID-19疫苗接种与SARS-CoV-2感染后心血管并发症风险的相关性:一项针对癌症患者的国际队列研究

2025-04-010
OAAI
Barriers to orthodox medical care of prostate cancer in Ghana
2025-01-070
OAAI
Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)

PTEN基因改变对初诊转移性前列腺癌(mPC)患者临床结局的影响

2024-09-010
PRE
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study

Pembrolizumab联合enzalutamide治疗转移性去势抵抗性前列腺癌在enzalutamide治疗进展: 2期主题199研究的队列4和5

2024-08-121
PRE
Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer
2024-07-171
PRE
Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis
2024-07-011
OAAI
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration
2024-02-223
OAAI
The impact of cancer metastases on COVID-19 outcomes: A COVID-19 and Cancer Consortium registry-based retrospective cohort study

癌症转移对新型冠状病毒肺炎结局的影响: 基于新型冠状病毒肺炎和癌症协会注册的回顾性队列研究

CANCER
IF5.1
2024-02-200
PRE
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study

乳腺癌和新型冠状病毒肺炎患者的临床特征,种族不平等和结局: 新型冠状病毒肺炎和癌症联盟 (CCC19) 队列研究

2023-10-172
OA
Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)
2023-10-015
OA
Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer
2023-09-186
OAAI